Table 1 Characteristics of studies included in the meta-analysis
Study | Region | Type | Duration | Inclusion criteria | Â | Intervention | N | Age | Male |
|---|---|---|---|---|---|---|---|---|---|
Metabolic syndrome | |||||||||
 Rahmani et al. 2016 [23] | Iran | RCT double-blind | 8 weeks | Patients with symptoms of MetS (NCEP-ATP III) and diagnosis of NAFLD | Case | Amorphous dispersion Curcumin (amorphous dispersion preparation, equivalent to 70 mg/d curcuminoids) | 37 | 46.37 ± 11.57 | 19 |
Control | Placebo | 40 | 48.95 ± 9.78 | 19 | |||||
 Amin et al. 2015 [26] | Pakistan | RCT double-blind | 8 weeks | Patients with ≥ 3 features of MetS, prediabetes, dyslipidemia and prehypertension | Case | Turmeric powder 2.4 g/d | 63 | 42.40 ± 13.70 | NA |
Control | Placebo | 63 | 41.57 ± 12.80 | NA | |||||
 Yang et al. 2014 [27] | Taiwan | RCT double-blind | 12 weeks | Patients with diagnosis of MetS (NCEP-ATP III) | Case | Turmeric extract (equivalent to 1890 mg/d curcuminods) | 30 | 59.03 ± 10.10 | 12 |
Control | Placebo | 29 | 59.61 ± 14.09 | 17 | |||||
Type 2 diabetes mellitus | |||||||||
 Rahimi et al. 2016 [24] | Iran | RCT double-blind | 3 months | Type 2 Diabetic patients | Case | Curcumin (nano-micelle 80 mg/day) | 35 | 56.34 ± 11.17 | 17 |
Control | placebo | 35 | 60.95 ± 10.77 | 14 | |||||
 Selvi et al. 2015 [25] | India | RCT | 4 weeks | Type 2 diabetic patients | Case | Turmeric powder 2 g/day +Metformin | 30 | 47.00 ± 7.17 | 30 |
Control | Metformin (1 g/day) | 30 | 46.80 ± 6.10 | 30 | |||||
 Chuengsamarn et al. 2014 [28] | Thailand | RCT double-blind | 6 months | Type 2 diabetic patients | Case | Turmeric extract (equivalent to 1500 mg/d curcuminods) | 107 | 59.16 ± 11.04 | 50 |
Control | Placebo | 106 | 59.58 ± 10.71 | 47 | |||||
 Usharani et al. 2008 [15] | India | RCT | 8 weeks | Type 2 diabetic patients | Case | Turmeric extract (equivalent to 600 mg/day curcuminoids) | 23 | 55.52 ± 10.76 | 12 |
Control | Placebo | 21 | 49.75 ± 8.18 | 11 | |||||